Prilenia
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders.
- Company typePrivate
- Founded2018
- HeadquartersHerzliya, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Prilenia does
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. The company was founded in 2018 and is based in Israel, the Netherlands, and Boston.
Prilenia firmographics
Firmographics- Name
- Prilenia
- Legal name
- Prilenia Therapeutics B.V.
- Website
- https://www.prilenia.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders.
- Ownership category
- akta.pro rank
Prilenia industry classification
Industry- Product category
- Neurodegenerative Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
- akta.pro secondary industries
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where Prilenia is headquartered
LocationHeadquarters
- HQ city
- Herzliya
- HQ country
- Israel
- HQ region
- Middle East
Offices3 records
Markets served
Prilenia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Revenue: Prilenia is a clinical-stage biotechnology company focused on developing pridopidine for Huntington's disease and ALS. The company is not yet generating revenue as the drug is still in clinical development and has not been approved by regulatory agencies.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Prilenia product offering
Product offeringCore offering
Prilenia develops pridopidine, an oral investigational drug (45 mg twice daily) and first-in-class selective sigma-1 receptor (S1R) agonist being advanced through Phase 3 clinical trials for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). The compound activates the S1R to stimulate multiple cellular protective pathways including autophagy, axonal transport, mitochondrial energy production, and calcium homeostasis, with a safety profile established across more than 1,700 studied patients and up to 7 years of long-term safety data. The company also operates expanded access programs such as the ACT for ALS protocol to provide pridopidine to patients not eligible for clinical trials.
Product overview
Prilenia is a clinical-stage biotechnology company developing pridopidine, a first-in-class oral sigma-1 receptor (S1R) agonist, as a disease-modifying treatment for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). The company's product portfolio centers on pridopidine (45 mg twice daily), which is advancing through Phase 3 clinical trials including PREVAiLS for ALS and a planned confirmatory trial for HD following the PROOF-HD study. Prilenia operates alongside strategic partnerships including a collaboration with Ferrer for European commercialization, expanded access programs (ACT for ALS), and data-sharing initiatives with CHDI Foundation. The company is incorporated in the Netherlands with operations across the U.S., Canada, Europe, and Israel.
Differentiator
Problem solved
Functional benefit
Brands
- Nurzigma: Brand name for pridopidine submitted for European marketing authorization (withdrawn in November 2025)
Products and services
- Pridopidine Pridopidine is an oral investigational drug (45 mg twice daily) and a highly selective, potent sigma-1 receptor (S1R) agonist in Phase 3 development for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). It activates the S1R to stimulate cellular protective pathways including autophagy, axonal transport, mitochondrial energy production, and calcium homeostasis. It has been studied in more than 1,700 people with long-term safety data available up to 7 years.
- ACT for ALS Expanded Access Program The ACT for ALS Expanded Access Program is an NIH NINDS-sponsored expanded access protocol for pridopidine, led by Massachusetts General Hospital's Sean M. Healey & AMG Center for ALS. It makes pridopidine available at treating sites across the U.S. for up to 200 ALS individuals not eligible for other clinical trials, with treatment duration of up to two years.
Quantifiable outcome
- Phase 2 HEALEY trial showed 32% slowing of overall disease progression, 62% slowing of respiratory function decline, 93% reduction in speech deterioration, and 57% improvement in survival benefit in rapidly progressive ALS subgroup
- +2 more outcomes
Companies that use Prilenia
Customer profileSegments3 records
Ideal customer profiles4 records
Prilenia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Prilenia partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- CHDI FoundationcorePrilenia entered into a Data Use Agreement with CHDI Foundation to provide clinical data from the placebo arms of its PRIDE and PROOF studies for Huntington's disease research. CHDI receives a worldwide, non-exclusive license to use individual patient-level data and can share it with qualified third-party research institutions. The collaboration aims to improve clinical trial design and support the development of more effective treatments for Huntington's disease.
- Healey ALS Center / NEALS ConsortiumcoreCollaboration with Mass General Brigham Healey ALS Center and NEALS (Northeast ALS Consortium) for the PREVAiLS Phase 3 trial. The first participant was enrolled at Mass General Brigham. The trial will include up to 60 treatment centers in 13 countries.
- FerrercoreIn April 2025, Prilenia and Ferrer entered into a collaboration and license agreement for the co-development and commercialization of pridopidine in Europe and other select international markets. The collaboration is valued at approximately $500 million. Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific. The partnership aims to bring pridopidine to HD and ALS patients as quickly as possible.
- Huntington Study Group (HSG)coreThe Huntington Study Group (HSG) is a world leader in clinical research for Huntington's disease and a valued collaborator for Prilenia. HSG conducted the PROOF-HD clinical trial. The group includes leading HD researchers and clinicians including Dr. Ralf Reilmann (European Lead PI) and Dr. Andrew Feigin (North American Lead PI).
- Mass General Hospital / Sean M. Healey & AMG Center for ALScorePrilenia collaborated with Massachusetts General Hospital's Healey ALS Center for the HEALEY ALS Platform Trial. The trial was conducted at 54 NEALS consortium sites. Dr. Merit Cudkowicz serves as principal investigator and sponsor of the HEALEY ALS Platform Trial.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
Prilenia competitors and assessment
Company assessmentDirect peers
- Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company developing treatments for Huntington's disease and ALS, including WVE-003 and ALS-targeted programs. Directly competes with Prilenia for the same patient populations and KOL relationships in HD/ALS.
- Amylyx Pharmaceuticals: Commercial-stage biotech focused on ALS with AMX0035 (Relyvrio) approved in the US and now pursuing additional neurodegenerative indications. Directly comparable in ALS positioning, disease-modifying mechanism narrative, and late-stage development profile.
- uniQure: Gene therapy company developing AMT-130 for Huntington's disease, in Phase 1/2 trials. Targets the same HD patient population with a different (gene-silencing) modality; both are private/clinical-stage HD-focused biotechs.
- Voyager Therapeutics: Clinical-stage gene therapy company with CNS-focused pipeline including programs for Huntington's disease and ALS. Competes for similar patient populations and partnership dollars with novel CNS-delivery platforms.
Broad incumbents
- Ionis Pharmaceuticals: Established antisense oligonucleotide leader with tominersen (co-developed with Roche) for HD and several ALS programs. Larger and broader platform, but directly competes in the same antisense/RNA-targeted HD space and adjacent ALS space.
- Biogen: Large CNS-focused biopharmaceutical company with tofersen (Qalsody) approved for SOD1 ALS and multiple HD-adjacent programs. Represents the broad incumbent in neurodegenerative disease with established commercial infrastructure overlapping Prilenia's targets.
- Sage Therapeutics: CNS-focused biotech with approved neurology products and a neurodegenerative pipeline including potential HD/ALS-adjacent indications. Comparable in CNS development focus, regulatory pathway experience, and rare neurology commercial strategy.
- PTC Therapeutics: Mid-sized rare disease biopharmaceutical company with SMA, Duchenne, and Huntington's disease programs (including PTC518, an oral splicing modulator for HD). Direct overlap in rare neurological indications and oral small-molecule HD strategy.
Emerging players
- Annexon Biosciences: Clinical-stage biotech developing complement-targeted therapies for neurodegenerative and autoimmune diseases including Huntington's disease. Similar stage and modality (anti-inflammatory/neuroprotective), competing for the same prescribers and investors.
Regional players
- PegBio: China-based clinical-stage biopharmaceutical company developing treatments for neurodegenerative and metabolic diseases, including ALS and rare neurological indications. Operates in a different geography but pursues comparable disease-modifying CNS mechanisms.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks1 record
Key highlights7 records
Customer concentration
Prilenia social profiles
Digital presencePrilenia compliance and trust
Trust signalCompliance4 records
Prilenia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prilenia leadership team
Management profileNumber of profiles
Profiles16 records
Prilenia funding detail
Funding detailFunding overview
Funding rounds2 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prilenia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prilenia
What does Prilenia do?
Prilenia develops pridopidine, an oral investigational drug (45 mg twice daily) and first-in-class selective sigma-1 receptor (S1R) agonist being advanced through Phase 3 clinical trials for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). The compound activates the S1R to stimulate multiple cellular protective pathways including autophagy, axonal transport, mitochondrial energy production, and calcium homeostasis, with a safety profile established across more than 1,700 studied patients and up to 7 years of long-term safety data. The company also operates expanded access programs such as the ACT for ALS protocol to provide pridopidine to patients not eligible for clinical trials.
Is Prilenia a public or private company?
Prilenia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Prilenia founded?
Prilenia was founded in 2018. It employs 11 to 50 people.
Where is Prilenia based?
Prilenia is headquartered in Herzliya, Israel, in the Middle East region.
How does Prilenia make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are Prilenia's main competitors?
Direct peers on record are Wave Life Sciences, Amylyx Pharmaceuticals, uniQure and Voyager Therapeutics. Broad incumbents are Ionis Pharmaceuticals, Biogen, Sage Therapeutics and PTC Therapeutics. Annexon Biosciences is listed as an emerging player. PegBio is listed as a regional player.
Does Prilenia have an API?
No public API is recorded for Prilenia.
What industry is Prilenia in?
Prilenia's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 8731.